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Abstract: Extensive intestinal resection impairs the absorptive capacity and results in 
short-bowel syndrome-associated intestinal failure (SBS-IF), when fluid, electrolyte, acid-base, 
micro-, and macronutrient homeostasis cannot be maintained on a conventional oral diet. Several 
factors, including the length and site of the resected intestine, anatomical conformation of the 
remnant bowel, and the degree of postresection intestinal adaptation determine the disease 
severity. While mild SBS patients achieve nutritional autonomy with dietary modification 
(eg, hyperphagia, small frequent meals, and oral rehydration fluids), those with moderate-to-
severe disease may develop SBS-IF and become dependent on parenteral support (PS) in the 
form of intravenous fluids and/or nutrition for sustenance of life. SBS-IF is a chronic debilitating 
disease associated with a poor quality of life, and carries significant morbidity and health care 
costs. Medical management of SBS-IF is primarily focused on individually tailored symptomatic 
treatment strategies, such as antisecretory and antidiarrheal agents to mitigate fluid losses, and 
PS. However, PS administration is associated with potentially life-threatening complications, 
such as central venous thromboses, bloodstream infections, and liver disease. In pursuit of a 
targeted therapy to augment intestinal adaptation, research over the past 2 decades has identi-
fied glucagon-like peptide, an intestinotrophic gut peptide that has been shown to enhance 
intestinal absorptive capacity by causing an increase in the villus length, crypt depth, and 
mesenteric blood flow and by decreasing gastrointestinal motility and secretions. Teduglutide, 
a recombinant analog of glucagon-like peptide-2, is the first targeted therapeutic agent to gain 
approval for use in adult SBS-IF. Teduglutide was shown to result in significant (20%–100%) 
reduction in PS-volume requirement and have a satisfactory safety profile in three randomized 
control trials. Further research is warranted to see if reduction in PS dependency translates to 
improved quality of life and reduced PS-associated complications.
Keywords: short-gut syndrome, intestinal adaptation, glucagon-like peptide-2, teduglutide
Introduction
By virtue of its length, the human gastrointestinal tract has an enhanced absorptive 
surface area and distinctly specialized segments of the small and large intestines 
that conduct diverse digestive functions. Intestinal resection indicated in such 
diseases as inflammatory bowel disease, trauma, mesenteric ischemia, congenital 
atresia, or malignancy diminishes the fluid and nutrient absorption due to the loss of 
absorptive capacity. Other conditions, such as radiation enteritis, chronic intestinal 
pseudo-obstruction, or congenital villous atrophy, also result in malabsorption due 
to defective intestinal function. Inability to maintain an adequate protein-energy, 
fluid, electrolyte, acid-base, and macro- or micronutrient balance when on a con-
ventionally accepted normal diet defines short-bowel syndrome-associated intestinal 
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failure (SBS-IF).1 Short segments of intestine can be resected 
without critically affecting fluid and nutrient absorption, 
especially when the colon is intact and in continuity. 
However, patients with loss of moderate-to-long segments 
of intestines (eg, patients with ,35 cm of jejunum with 
jejunoileal anastomosis, ,60 cm with jejunocolonic anasto-
mosis, or ,115 cm with end jejunostomy) require parenteral 
fluids and/or nutrients for sustenance of life.2
SBS has protean manifestations that are heterogeneous 
in both severity and diversity, which depend on the underly-
ing etiology and disease activity, length and site of intestine 
resected, and whether the colon is retained. Diarrhea or high 
stomal output is the most common and debilitating symp-
tom, while dehydration, nausea, fatigue, weight loss, failure 
to thrive, and stigmata of protein-energy malnutrition and 
micronutrient deficiencies are other common manifestations 
of malabsorption. Extraintestinal manifestations, such as 
nephrolithiasis, cholestatic liver disease, and osteoporosis, 
are common and caused by the metabolic derangements 
resulting from malabsorption. Distressing symptoms, such 
as chronic pain and diarrhea, frequent health care visits or 
hospitalizations, loss of workdays, and caregiver strain, con-
tribute to an overall poor quality of life (QoL) and consider-
able emotional, as well as financial stress. SBS is a chronic 
debilitating disease with significant morbidity and mortality, 
and the health care burden is enormous, with annual costs 
estimated to be as high as US$150,000 per patient. The exact 
incidence and prevalence are difficult to determine, due to 
disease heterogeneity and lack of proper databases. Based on 
the fact that nearly a third of the home parenteral nutrition 
(PN)-dependent patients have SBS, approximately 10,000 
(as per a 1992 report) patients were believed to have SBS-IF 
in the US, while its prevalence is estimated to be four per 
million in European nations.3,4 However, the real numbers 
are believed to far exceed these estimates, as they represent 
only a proportion of SBS patients reported by academic and 
tertiary care centers.
Parenteral support (PS) in the form of PN and/or intrave-
nous fluids has been the cornerstone of supportive treatment 
for SBS-IF since the advent of total PN in the 1960s, which has 
saved the lives of those who have lost their intestinal function. 
However, PS is associated with metabolic (eg, hyperglyce-
mia and PN-associated liver disease) and indwelling central 
venous catheter-associated complications (eg, venous throm-
boses and blood stream infections) that can be potentially life-
threatening. Until recently, adjunctive pharmacotherapy has 
been available primarily for symptom control and provided 
supportive care. In an effort to minimize PN dependency using 
therapeutic agents that could augment intestinal absorptive 
capacity, research in the field has explored the mechanisms 
underlying intestinal adaptation. A host of gut peptides, such 
as glucagon-like peptide (GLP)-2, epidermal growth factor, 
insulin-like growth factor, gastrin, insulin, and cholecysto-
kinin, have been shown to mediate intestinal adaptation.5 
Teduglutide, a synthetic analog of GLP-2, was the first to 
show promising intestinotrophic properties in experimental 
studies. It was shown to be clinically effective in multiple 
randomized controlled trials (RCTs) by causing a significant 
reduction in the PS-volume requirement in SBS-IF patients.6,7 
In this review, we focus on the role of teduglutide as the first 
targeted therapeutic agent approved by the US Food and Drug 
Administration (FDA) for the management of adult SBS-IF 
patients in the US.
Management of SBS-IF
A coordinated care approach by a multidisciplinary team of 
gastroenterologists, surgeons, pharmacists, dieticians, and 
nurses is crucial for successful intestinal rehabilitation.8 
The majority of SBS patients achieve nutritional autonomy 
through intestinal adaptation, compensatory “hyperphagia”, 
and dietary modification. However, patients with massive 
intestinal resection, active underlying disease, absent colon, 
high-output stoma, poor intestinal rehabilitation care, and/or 
multiple comorbid conditions require long-term or indefi-
nite PS. Surgical reconstruction and tailoring procedures to 
increase the intestinal absorptive surface area and intestinal 
transplantation are performed in a select group of patients 
who fail medical rehabilitation, but are available in very 
few experienced tertiary care centers. Treatment strategies 
are individually tailored, with titration of medication dose 
and frequency and PS volume and constitution guided by 
the patient’s clinical and laboratory markers of fluid and 
nutritional balance.9
Pharmacotherapy
In the past, management of SBS patients was predominantly 
supportive, using pharmacotherapeutic agents to minimize 
gastrointestinal fluid losses by controlling diarrhea or 
high stomal output. Antidiarrheal agents (eg, loperamide, 
diphenoxylate, and codeine) and antisecretory agents 
(eg, proton-pump inhibitors) formed the bulk of the treat-
ment armamentarium. Somatostatin and its analog octreotide 
have been used to minimize refractory high-output stomal 
fluid losses by inhibiting gastric, pancreatic, and intestinal 
secretions.10 However, somatostatin usage has been found 
to affect enteral utilization of amino acids for splanchnic 
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protein synthesis and interfere with physiologic postresection 
adaptation.11 In a small (n=43) randomized placebo-controlled 
study of SBS adults (.3,000 calories/week of PN support 
and #200 cm of remnant small intestine), growth hormone 
(GH), glutamine (Gln), and a modified diet were given for 
4 weeks, with the latter two continued for a total of 3 months.12 
Patients receiving GH and GH + Gln achieved significantly 
more weaning from PN when compared to those who received 
Gln, and only those who received GH + Gln + modified diet 
had maintained that effect at 3 months. Importantly, patients 
with end jejunostomy did not benefit from it. Zorbtive® 
(somatropin [recombinant GH]) was approved in 2003 for 
managing refractory fluid and electrolyte derangements. 
However, a Cochrane review noted that the benefits of weight 
gain and energy absorption with the use of human GH were 
temporary, and its adverse effects, including manifestations 
of acromegaly, limited its long-term clinical utility.13 For 
several years, there was no targeted treatment for SBS until 
teduglutide was approved in 2012.
Intestinal adaptation and the role  
of GLP-2
After resection, the remnant intestine undergoes structural and 
functional remodeling changes known as intestinal adapta-
tion, which begin in the immediate postsurgical period and 
continue for up to 2 years. The adaptation process allows 
recovery of varying degrees of intestinal absorptive capa-
city through intestinal epithelial hyperplasia; increase in 
villous height, crypt depth, and intestinal length and caliber; 
enhanced intestinal blood flow; and increased expression 
of the epithelial transporter proteins.14 Adaptation has been 
noted to be more robust among patients who are younger, 
have proximal rather than distal intestinal resection, maintain 
oral or enteral nutrition that stimulates the remnant intesti-
nal mucosa, have an intact ileocecal valve and mesenteric 
circulation, and have fewer comorbid conditions. Among 
several intestinal peptides that have been studied in pursuit 
of a targeted therapy to enhance the absorptive capacity 
of remnant intestine, GLP-2 emerged as the front-runner. 
GLP-2 was shown to promote mucosal growth by enhancing 
crypt-cell growth and inhibiting apoptosis, decreasing gastric 
motility and secretions, increasing mesenteric blood flow, and 
reinforcing gut-barrier function in both animal and human 
studies.15 It is a 33-amino acid-long peptide that is secreted 
in response to luminal nutrients by the enteroendocrine L cell 
located in the distal ileum and colon. Endogenous GLP-2 
undergoes rapid enzymatic degradation by the exopeptidase 
dipeptidyl peptidase IV, precluding its clinical utility.
Teduglutide
Pharmacology
Teduglutide is a human recombinant analog of GLP-2 with 
N-terminal substitution of glycine for alanine at position 2, 
rendering it resistant to dipeptidyl peptidase-IV degrada-
tion and thereby prolonging the half-life from ∼7 minutes 
to up to ∼3 hours and enabling its pharmacological utility.16 
Teduglutide is believed to act by binding to the intestinal GLP-2 
receptors and potentiating the GLP-2 effect that is mediated by 
a complex signaling pathway. It is administered once a day, and 
has approximately 87% bioavailability when injected subcuta-
neously with a volume of distribution of 103 mL/kg. It is elimi-
nated via the kidneys, and a 50% dose reduction is recommended 
in patients with moderate-to-severe renal impairment.
Clinical effectiveness
Preclinical and earlier clinical trials have been outlined and 
described in detail in one of our earlier reviews with the key 
clinical trials outlined in Table 1.17 In preclinical animal stud-
ies, teduglutide was shown to increase villus height, crypt 
depth, and glucose transport.18
Phase ii study
In an open-label, non-placebo-controlled Phase II study, 
teduglutide was given to 16 adult SBS patients for 3 weeks, 
and metabolic balance studies were performed to measure 
the effect.19 Teduglutide was shown to cause a significant 
decrease in fecal wet weight excretion and fecal energy 
loss, as well as a significant increase in absolute wet weight 
absorption and urine wet weight. Intestinal biopsies of these 
subjects revealed significant increase in villus height, crypt 
depth, and mitotic index, supporting the drug’s intesti-
notrophic action. After discontinuation for 3 weeks, all these 
drug effects reversed.
Phase iii studies
In the first Phase III RCT (n=83), teduglutide was given 
to SBS-IF subjects for 24 weeks at two different doses 
(0.05 mg/kg/day and 0.10 mg/kg/day) versus placebo, and 
a reduction in the PS requirement was measured during 
the treatment period.6 A special weaning algorithm was 
used to allow gradual reduction of the PS volume guided 
by the increase in urine output .2 L/day in order to main-
tain fluid balance. Subjects who had a reduction of $20% 
of their weekly PS volume at week 20 and maintained 
through week 24 were labeled “responders”. The responder 
rate was initially used as the primary end point, but was 
expanded to a graded response score that accounted for the 
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duration (response at week 16 through week 20 and week 20 
through week 24) and intensity (20%–100% reduction) of the 
response to characterize the drug effect better. Teduglutide 
achieved the primary end point (graded response score) at 
0.05 mg/kg/day in 16 of 35 subjects (P=0.007), but surpris-
ingly not at 0.10 mg/kg/day (8 of 32) versus the placebo group 
(P=0.16). In their ad hoc analysis, the investigators noted that 
higher baseline PS volume among the 0.10 mg/kg/day dose 
group and limitation of no more than 10% reduction of PS 
volume and at no earlier than 4-week intervals could have 
caused the dose–effect discrepancy in their analysis. In addi-
tion, significant increases in secondary end points, including 
lean body mass, total body bone mineral content, intestinal 
villus height, and plasma citrulline levels (biomarker for 
enterocyte mass in SBS patients), were seen in the two 
teduglutide-dose groups compared with placebo.
In an open-label “extension” study, 52 subjects continued to 
receive the same dose of teduglutide for an additional 28 weeks 
beyond the 24 weeks of the first Phase III RCT.20 Progressive 
drug effect was noted at both doses at 52 weeks, with .20% 
reduction in PN noted in 68% of patients in the 0.05 mg/kg/day 
group and 52% of patients in the 0.10 mg/kg/day group and 
a reduction of $1 day/week of PN dependence noted in 68% 
and 37%, respectively. Interestingly, four subjects achieved 
complete independence from PS. The safety profile was similar 
to that of the earlier RCT, with headache (35%), nausea (31%), 
and abdominal pain (25%) being the most commonly reported 
adverse events. Overall, seven patients dropped out because 
of the adverse events, with four of them citing gastrointestinal 
symptoms as the main reason.
In the second multicenter confirmatory RCT (STEPS 
[Study of Teduglutide Effectiveness in Parenteral nutrition 
dependent Short bowel syndrome subjects]; n=86), teduglutide 
was administered at a single dose level of 0.05 mg/kg/day 
for 24 weeks versus placebo.7 PS volume was reduced by 
10%–30% every 2 weeks, as permitted by stable hydration and 
nutritional status assessed by urine output, urine sodium, and 
clinical and laboratory testing performed at regular intervals. A 
20%–100% reduction in PS volume at week 20 through week 
24 was considered a “response”, and the percentage of subjects 
demonstrating this – the response rate – was measured as the 
primary end point, and was noted among 63% (27 of 43) sub-
jects in the teduglutide group compared to 30% (13 of 43) in the 
placebo group (P=0.002). As the secondary end point, a mean 
PS-volume reduction of 4.4±3.8 L/week (32%±19%) was 
noted in the teduglutide group compared to a 2.3±2.7 L/week 
(21%±25%) reduction noted in the placebo group. Among 
the exploratory end points, when compared to placebo, the 
teduglutide group had a higher responder rate at week 24 (77% 
[30 of 39] versus 46% [18 of 39]) and higher percentage of 
patients with $1 day/week reduction of PS (54% [21 of 39] 
versus 23% [9 of 39]). The fluid-composite effect, representing 
the sum of increase in the urine output, decrease in the PS vol-
ume, and the oral intake, was measured as the clinical indictor 
of intestinal absorption. Fluid-composite effect reduction was 
higher among the teduglutide group at all visits, particularly 
at week 24 when the mean ± standard deviation reduction 
was 5.4±6.0 L/week in the teduglutide group compared to a 
reduction of 1.1±4.3 L/week in the placebo group (P=0.0006). 
Overall, the adverse-effect profile was comparable between the 
groups, with treatment-emergent adverse events noted in 36% 
of the treatment group compared to 28% of the placebo.
To investigate the residual effects of teduglutide, 
37 patients from the first RCT who had received the drug 
for at least 24 weeks were followed up for 12 months after 
drug discontinuation.21 Data on PS-volume changes and 
body mass index (BMI) were collected retrospectively. When 
compared to patients who had stable (n=15) and decreased 
(n=7) PS by 12 months, those who had an increased (n=15) 
PS requirement were noted to have shorter colons and less 
often had their colon in continuity. Also, only the latter group 
had decreased BMI at 3, 6, and 12 months since their first 
off-drug visit (P=0.001). The investigators noted that the 
change in BMI off-drug was predicted by colon and small 
bowel length, baseline BMI, and on-drug change in PN vol-
ume (adjusted R2 =0.708). While it is interesting to note that 
patients had decreased PS even after drug discontinuation, 
the study had several limitations, including its small size and 
shorter duration, descriptive nature, and lack of nutritional 
balance studies or measures of body composition.
Dosing and prescription
Teduglutide has been approved by the FDA since December 
2012 under the trade name of Gattex®, and by the European 
Medicines Agency since June 2012, where it is marketed 
as Revestive®. The FDA recommends teduglutide at a dose 
of 0.05 mg/kg/day, to be administered once a day subcu-
taneously in the arms, thighs, or abdomen and by rotating 
the injection sites.22 Patients with a creatinine clearance 
of #50 mL/minute or end-stage renal disease require a 50% 
dose reduction.23 It is dispensed in a powdered form that 
needs to be reconstituted and used within 3 hours.
Safety and tolerability
Overall, abdominal pain (30%), minor injection-site reac-
tions (22%), nausea (18%), headaches (16%), abdominal 
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distension (14%), upper-respiratory tract infection (12%), 
and fluid overload (12%) were the most commonly reported 
adverse effects. The “-trophic” nature of the drug poses a 
concern for its potential for tumor initiation and/or promo-
tion, but experimental evidence from animal models has not 
demonstrated a convincing proneoplastic effect, and there 
were no features of dysplasia in either of the small and large 
intestinal biopsies obtained at 24 weeks in the first RCT. 
However, three male subjects were noted to have malignan-
cies during the clinical trials. Two of them had extensive 
smoking history and were diagnosed with lung cancer after 
3 and 12 months of exposure to teduglutide. The third patient 
was diagnosed with a metastatic adenocarcinoma of unknown 
primary origin after 11 months, but was found to have a 
previously unrecognized liver lesion and remote history 
of Hodgkin’s lymphoma treated with abdominal radiation 
2 decades earlier. Teduglutide is contraindicated in patients 
with active gastrointestinal malignancy, and its risks and ben-
efits need to be weighed before being prescribed to patients, 
including those with nongastrointestinal malignancies. 
Colonoscopic examination and removal of any colorectal 
polyps is recommended within 6 months prior to initiation 
of teduglutide. Subsequently, surveillance colonoscopy is 
recommended at the end of 1 year and then every 5 years or 
more frequently as needed.
Cost and availability
The estimated cost of teduglutide is reported to be approxi-
mately $300,000/year/patient.22 While it is very expensive 
and pharmacoeconomic models have not been conducted yet, 
the drug is expected to offset some of the economic burden 
of SBS-IF, which has an estimated health care expenditure 
of up to $500,000/year/patient.22
Patient perspective
SBS-IF patients experience impaired QoL stemming from the 
distressing physical symptoms, such as diarrhea and the need 
for regular PS administration, that cause significant restric-
tion of social life. QoL was assessed in the second Phase III 
RCT using a validated SBS-QoL scale at baseline and every 
4 weeks.24 PS-volume reductions were associated with signifi-
cant improvement in the total SBS-QoL score and the score 
of 9 of 17 items at 24 weeks in the teduglutide group when 
compared to baseline. However, the effect was not statistically 
significant when compared with the placebo group, which 
in the investigators’ opinion was probably due to the short 
observation period, imbalances in oral fluid intake in relation 
to PS reductions, large patient and effect heterogeneity, and 
occurrence of gastrointestinal adverse effects in a subgroup 
of teduglutide-treated patients. Importantly, the study was 
not powered to find significant differences in QoL. Further 
studies and greater experience with drug usage is necessary to 
understand the impact of teduglutide on the patient’s QoL.
Conclusion
Management of SBS-IF is predominantly supportive, includ-
ing dietary modification, antidiarrheal and antisecretory 
drugs, and infusion of PS. While PS is life-saving, QoL 
is restricted by high stomal or diarrhea losses, recurrent 
catheter-related infections, and potentially life-threatening 
complications, such as liver disease and central venous 
access-related thromboses. In search of a targeted therapy 
to augment intestinal absorptive capacity, several gut fac-
tors that participate in intestinal adaptation process have 
been studied for their therapeutic potential. GLP-2 is a 
pluripotent gut peptide with intestinotrophic actions, but 
an extremely short half-life precluded its clinical utility. 
Teduglutide, a recombinant analog of GLP-2 that is resistant 
to degradation by endogenous protease, has been shown to 
decrease the need for PS in adult SBS patients. With the 
recent approval of teduglutide, the medical management 
of SBS-IF has transformed from being supportive care to a 
more targeted therapy. Whether the reduction in PS volume 
translates to improvement in patient QoL and mitigation of 
PS-associated complication rates is yet to be seen. Further 
studies on long-term outcomes and cost-effectiveness analy-
ses are needed to appreciate the true efficacy and impact of 
this expensive drug.
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